Nutrition

Jaguar Health Reports Second Quarter 2025 Financials: Net Q2 2025 Revenue Up Approximately 35% Versus Net Q1 2025 Revenue

The combined net Q2 2025 revenue of approximately $3.0 million for prescription and non-prescription products, including license revenue, increased approximately…

5 months ago

Synergy CHC Corp Reports Second Quarter 2025 Financial Results and its Tenth Consecutive Quarter of Profitability

WESTBROOK, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a consumer health…

5 months ago

Parents Urged to Make Kids’ Bedtime Screen-Free as National Campaign Launches with NYC Flash Mob

"Screen-Free Sleep" movement takes to the streets to address America's youth sleep crisis NEW YORK, Aug. 14, 2025 /PRNewswire/ --…

5 months ago

Vitanergy Health US Inc. Launches Three New Dietary Supplements to Support Women’s Daily Wellness

Now available on Amazon, Walmart Marketplace, Flaire.com, and Vitanergy.com—Formulated with high-quality ingredients and made in the USA. LAS VEGAS, Aug.…

5 months ago

Protera Health Integrates with Epic to Deliver Seamless Digital MSK Care for Health Plans and Health Systems

DETROIT, Aug. 13, 2025 /PRNewswire/ -- Protera Health, a leading physician-led digital musculoskeletal (MSK) care solution, today announced its integration with…

5 months ago

CV Sciences, Inc. Reports Second Quarter 2025 Financial Results

SAN DIEGO, CA / ACCESS Newswire / August 13, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our",…

5 months ago

Plug and Play Topeka Selects New Cohort of Nine Animal Health Startups for Accelerator Program

Emerging companies from six countries begin the 18-week startup program in Kansas' capital city TOPEKA, Kan., Aug. 13, 2025 /PRNewswire/ -- In…

5 months ago

Aspire Biopharma Successfully Launches BUZZ BOMB(TM) Pre-Workout Supplement at FitCon and FitExpo, Two of the Largest Fitness Conventions in the World

BUZZ BOMB™ is bringing its unique delivery technology benefits to the multi-billion-dollar pre-workout to help athletes and fitness enthusiasts maximize…

5 months ago

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical…

5 months ago

Aligos Therapeutics Announces First Subject Dosed in the Phase 2 B-SUPREME Study of ALG-000184 in Subjects with Chronic HBV Infection

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical…

5 months ago